Hemanext is a leading innovator in blood processing, storage, and transfusion technology.
Hemanext is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.
Hemanext was founded in 2004 by Martin Cannon. The company is headquartered in Lexington, Massachusetts and manufacturing operations in Avon MA.
Hemanext's research and development efforts center on the study of hypoxically stored red blood cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs by limiting oxygen and carbon dioxide levels in the storage environment.
Hemanext launched Hemanext ONE® RBC (Red Blood Cell) Processing and Storage System, a new hypoxic storage method, which might improve the quality of life for patients that require chronic and high-volume transfusions, including people with thalassaemia and other haemoglobin disorders.
Hemanext entered into distribution agreements with two leading medical device distributors in the Nordics and Italy, bolstering its sales capabilities across key European markets and strengthening its relationships with top blood centers and clinicians in each region.
Hemanext is backed by Omega Family Office, NIH, Antaeus Enterprises, The Testa Family Office, Grabe Family Office, The Eduardo Avayu Family Office, and others. The company raised $18M in Series B round on Nov 07, 2022. This brings Hemanext's total funding to around $130M to date.